Amgen Submits MAA to EMA for ABP 501
Amgen submitted a market authorization application to EMA for ABP 501, a biosimilar candidate to Humira.
On Dec. 4, 2015, Amgen announced the submission of a marketing authorization application (MAA) to the European Medicines Agency (EMA) for ABP 501, a biosimilar candidate to Humira (adalimumab). This is Amgen’s first biosimilar submission to the European Union (EU).
ABP 501 is a biosimilar candidate to adalimumab, an anti-TNF-α monoclonal antibody, which is approved in many countries for the treatment of various inflammatory diseases. Phase III comparative efficacy and safety studies were conducted in moderate-to-severe plaque psoriasis and moderate-to-severe rheumatoid arthritis. According to the company, the results showed clinical equivalence to adalimumab.
The company submitted a biologics license application (BLA) for ABP 501 to FDA in late November 2015. CEO Bob Bradway, said the company expects legal pushback from AbbVie, the original developer of Humira. AbbVie CEO, Richard Gonzalez, said they plan to aggressively defend patents for Humira, which he says will protect the product until 2022.
Source: Amgen
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
